13 results about "Phylum Bacteroidetes" patented technology

The invention discloses a bifidobacterium animalis subsp. Lactis BA-C53 and an application of the bifidobacterium animalis subsp. Lactis BA-C53 in products for improving bone health. The bifidobacterium animalis subsp. Lactis BA-C53 is classified and named as bifidobacterium animalis subsp. Lactis Bifidobacterium animalis subsp. Lactis BA-C53, the preservation number is CCTCC NO: M 2024460, the preservation unit is China Center for Type Culture Collection, and the preservation time is March 11, 2024. The bifidobacterium animalis subsp. Lactis BA-C53 can effectively improve the steady state of intestinal flora of a mouse with osteoporosis induced by estrogen deficiency, so that the relative abundance of phylum firmicalis and phylum actinomycetes is increased, the relative abundance of phylum bacteroides is reduced, and then short-chain fatty acid is generated to activate intestinal immunity and maintain the integrity of an intestinal barrier, so that the osteoporosis caused by estrogen deficiency is inhibited. Meanwhile, osteoclast differentiation can be inhibited by regulating NFATC1, RANKL and OPG pathways, then osteoporosis is relieved, and the compound can be widely applied to preparation of food and drugs.

The present invention provides a compound of Formula (I), which can be used to prepare a composition for losing weight and improving gut microbiota composition. The invention also provides a composition comprising an effective amount of the compound, which has the ability to increase the abundance of Bacteroidales, thereby reducing the ratio of Firmicutes to Bacteroidetes, and can increase the abundance of beneficial gut bacteria and change the gut microbiota composition. The compound and composition of the invention can be applied in food, medicine, feed, nutritional supplements and other uses.

The invention relates to the technical field of medicine, and particularly discloses a liver cirrhosis specific intestinal flora marker composition and application of the liver cirrhosis specific intestinal flora marker composition in noninvasive diagnosis. The intestinal microbial flora is selected from the group consisting of clostridium, Bacteroides, Thalictrum, Wehonor genus, Streptococcus genus, Klebsiella genus, and Prevotella genus; according to the method, a non-invasive solution is provided for screening and diagnosis of liver cirrhosis by detecting a synergistic change mode of specific florae such as clostridium, bacteroides, thickenella, prevotella, Wehonor, streptococcus and klebsiella in an excrement sample; the limitation that traditional liver needle biopsy is invasive and imaging examination is insensitive to early-stage lesions is avoided.

The application discloses a microorganism marker combination for identifying nest susceptibility of chickens and application thereof, and belongs to the technical field of poultry breeding and microbiomics. The microorganism marker combination comprises relative abundance information of at least two bacterial phyla in Bacteroidetes, Firmicutes and Verrucomicrobia in cecal contents. When at least two of the following conditions are met: the abundance of Bacteroidetes is higher than 35%, the abundance of Firmicutes is lower than 35%, and the abundance of Verrucomicrobia is lower than 2%, it is determined that the chicken has nest susceptibility or is in a nest period. Based on the marker combination, the application provides a corresponding identification method, a regulation method and a regulation agent screening strategy.

The main objective of the present invention is to provide a lactic acid bacterial strain and a composition for improving gut microbiota composition. The composition comprises the lactic acid bacterial strain and / or extracellular vesicles secreted by the lactic acid bacterial strain. Another objective of the present invention is to provide a method for improving gut microbiota composition and products of the lactic acid bacterial strain. Additionally, the composition of the present invention has the capability to influence the growth of Firmicutes and Bacteroidetes, thereby leading to an improvement in gut microbiota composition.

The invention belongs to the technical field of intestinal flora transplantation, and discloses an intestinal flora capsule for precise intestinal flora transplantation and a preparation method and application thereof. The invention provides application of a composition comprising maltodextrin and a cellulose ether derivative in preparation of an intestinal flora colonization accelerant. In the composition, due to the synergistic effect of the maltodextrin and the cellulose ether derivative, not only can intestinal flora be effectively protected from ultralow-temperature damage, but also the cell structure, functionality, cell metabolic activity and microenvironment adaptability required by colonization of the firmicite bacteria and the Bacteroides bacteria can be optimized, and the composition can be used for preparing the medicine for treating the intestinal tract diseases and the intestinal tract diseases. The freeze-drying protective agent has the effect of improving the colonization rate of the phylum firmicalis bacteria and the phylum bacteroides bacteria, can be used as a freeze-drying protective agent and a colonization accelerant of the intestinal flora at the same time, and has very excellent application prospects in preparation of products such as intestinal flora capsules and the like.

The invention relates to an application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for improving Parkinson's disease. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The brand new application of the BLa80 strain of the animal bifidobacterium subsp. Lactis is developed, namely the BLa80 strain is used for improving the Parkinson's disease, specifically, the BLa80 strain can weaken the cytotoxicity of 6-OHDA induced SH-SY5Y cells, relieve weight loss of MPTP induced subacute Parkinson's disease model mice, relieve dyskinesia of the mice and improve the Parkinson's disease. According to the present invention, the mice are subjected to the mouse striatum activation, such that the dopaminergic neuron is protected, the dopamine content in the mouse striatum is increased, the intestinal inflammation is relieved, the ratio of the thick-wall mycophylum to the bacteroides in the mouse intestinal flora is increased, the intestinal beneficial flora abundance is improved, and the intestinal flora diversity is increased;

The invention discloses exosome vesicle nano-selenium as well as a preparation method and application thereof, the exosome vesicle nano-selenium is prepared by adopting a lactic acid bacteria strain YKX which is screened out from a selenium-rich area and has a high nano-selenium conversion rate, and the influence of the exosome vesicle nano-selenium on mouse glycolipid metabolism disorder based on intestinal flora is studied; results show that the nano-selenium slows down weight increase and obesity of mice to a certain extent; the content of total cholesterol, total triglyceride and low-density lipoprotein cholesterol in serum of obese mice is reduced, and the content of high-density lipoprotein cholesterol is obviously increased; secondly, the intervention of the nano-selenium slows down the increase of the abundance of the mouse intestinal tract thick-wall mycophylum induced by high diet to a certain extent at the phylum level, improves the abundance of bacteroides and the overall diversity of the intestinal flora of the mouse, and improves the disorder of the intestinal flora; and finally, the nano-selenium intervenes in a metabolite level of intestinal microorganisms, so that the content of short-chain fatty acid is increased.

The invention relates to application of fucoidan polysaccharide sulfate in preparation of an inflammation protective agent and an intestinal flora regulator for young muscovy ducks against goose parvovirus infection. The invention provides application of fucoidan polysaccharide sulfate in preparation of a young muscovy duck anti-goose parvovirus infection preparation. The application specifically comprises an anti-inflammatory protective agent for young muscovy ducks against goose parvovirus infection and a flora regulator for repairing and regulating intestinal flora. The protection effect and mechanism of the fucoidan polysaccharide sulfate on the GPV infected young muscovy ducks are explored, and in-vitro and in-vivo experiments are respectively carried out. Results show that medium and high doses of fucoidan polysaccharide sulfate can significantly reduce the content of pro-inflammatory factors in serum and target organs, recover the level of anti-inflammatory factors and relieve tissue inflammatory damage. Microflora analysis results show that medium and high doses of fucoidan polysaccharide sulfate can reverse intestinal flora diversity decline caused by GPV infection, regulate abundance of dominant phylum such as phylum firmicalis and phylum bacteroides, and enrich beneficial bacteria such as Ackermann muciniphila.

The invention discloses application of lactobacillus reuteri in preparation of a medicine for preventing and treating colitis. Lactobacillus reuteri LR1 can act on at least two of the following items: regulating protein expression of NLRP3, Caspase-1 and IL-18 in colon tissues; the relative abundance of bacteroides, actinomycetes and myxomycetes in intestinal flora is changed; the content of intermediary amines, hypoxanthine and inosine in colon tissues is influenced; the colitis comprises ulcerative colitis, Crohn's disease and DSS-induced experimental colitis. The invention relates to the technical field of biological medicines. According to the application of the lactobacillus reuteri in preparation of the medicine for preventing and treating the colitis, the processes of enteric coating, microencapsulation and the like are adopted, an acrylic resin IV coating material and a sodium alginate-CaCl2 curing system are matched, lactobacillus reuteri LR1 can be prevented from being damaged by gastric acid, viable bacteria are ensured to directly reach colon to play a role, meanwhile, the survival rate of the viable bacteria is larger than or equal to 90% through the freeze-drying process, and the survival rate of the viable bacteria is larger than or equal to 90%. After an acceleration test is performed for 6 months, relatively high activity is still maintained, and stable pesticide effect is guaranteed.

The application discloses application of Qijiao Shengbai capsules in preparation of medicines for regulating intestinal microorganism flora disorder. The Qijiao Shengbai capsule is composed of Xue Renshen, Huangqi, Ajiao, Danggui, Da Zao, Ku Shen and Yinyanghe. By using the Qijiao Shengbai capsule, the microorganism flora is increased in the level of Firmicutes, increased in the level of Proteobacteria, reduced in the level of Bacteroidetes, reduced in the level of Akkermansia muciphila, and reduced in the level of Actinobacteria; in the level of genus, the microorganism flora is increased in the level of Prevotella, increased in the level of Lactobacillus, increased in the level of Parabacteroides, reduced in the level of Bacteroides, reduced in the level of Enterobacter, and reduced in the level of Staphylococcus, so as to regulate the intestinal microorganism flora. The application provides a new idea for research and development of medicines for preventing and treating intestinal flora disorder.

The application discloses an intestinal microorganism marker for mesenchymal stromal cells treating Crohn's disease, a product and application thereof, and provides the intestinal microorganism marker, which comprises one or more of the following: order of erysipelotrichales, genus of faecalibacterium, family of erysipelotrichaceae, class of bacilli, order of lactobacillales, family of lactobacillaceae, genus of lactobacillus, phylum of firmicutes, family of muribaculaceae, order of bacteroidales, class of bacteroidia, phylum of bacteroidetes, class of clostridia, order of lachnospirales, family of lachnospiraceae, class of clostridia UCG-014 and order of oscillatolales. The content or abundance of the above marker can be detected to predict the curative effect of mesenchymal stromal cells treating Crohn's disease. The application further provides a method for constructing a curative effect prediction model based on the above marker, and obtains the curative effect prediction model. The application can realize the early prediction of the curative effect of mesenchymal stromal cells treating Crohn's disease, and has a good clinical application prospect.

The main purpose of the present invention is to provide a Monascus pilosus strain and a composition for weight loss and improvement of gut microbiota composition. The composition comprises Monascus pilosus and / or its fermented product, or comprises an active ingredient of its fermented product. Another objective of the present invention is to provide a use of Monascus pilosus in the manufacture of a composition for weight loss and improvement of gut microbiota composition. The composition of the present invention has the ability to reduce body weight and improve gut microbiota, such as lowering the ratio of Firmicutes to Bacteroidetes.